Omega Therapeutics Inc
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epig… Read more
Omega Therapeutics Inc (OMGA) - Net Assets
Latest net assets as of September 2024: $11.54 Million USD
Based on the latest financial reports, Omega Therapeutics Inc (OMGA) has net assets worth $11.54 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($152.73 Million) and total liabilities ($141.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.54 Million |
| % of Total Assets | 7.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 0.96 |
Omega Therapeutics Inc - Net Assets Trend (2019–2023)
This chart illustrates how Omega Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Omega Therapeutics Inc (2019–2023)
The table below shows the annual net assets of Omega Therapeutics Inc from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $58.02 Million | -45.25% |
| 2022-12-31 | $105.97 Million | -47.18% |
| 2021-12-31 | $200.63 Million | +410.44% |
| 2020-12-31 | $-64.63 Million | -79.93% |
| 2019-12-31 | $-35.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Omega Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29785600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.00K | 0.09% |
| Other Comprehensive Income | $-14.00K | -0.02% |
| Other Components | $392.61 Million | 676.73% |
| Total Equity | $58.02 Million | 100.00% |
Omega Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Omega Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Argeo AS
OL:ARGEO
|
$1.05 Million |
|
Activex Ltd
AU:AIV
|
$1.05 Million |
|
CONOCOPHILLIPS (YCP.SG)
STU:YCP
|
$1.05 Million |
|
Zeder Investments Ltd
JSE:ZED
|
$1.06 Million |
|
Cyber Security 1 AB
ST:CYB1
|
$1.05 Million |
|
Argus SA
RO:UARG
|
$1.05 Million |
|
Dixie Gold Inc
PINK:YWRLF
|
$1.05 Million |
|
KBC GR (KDB.SG)
STU:KDB
|
$1.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Omega Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 105,971,000 to 58,016,000, a change of -47,955,000 (-45.3%).
- Net loss of 97,428,000 reduced equity.
- New share issuances of 40,000,000 increased equity.
- Other comprehensive income increased equity by 465,000.
- Other factors increased equity by 9,008,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-97.43 Million | -167.93% |
| Share Issuances | $40.00 Million | +68.95% |
| Other Comprehensive Income | $465.00K | +0.8% |
| Other Changes | $9.01 Million | +15.53% |
| Total Change | $- | -45.25% |
Book Value vs Market Value Analysis
This analysis compares Omega Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.75 | $0.05 | x |
| 2020-12-31 | $-1.35 | $0.05 | x |
| 2021-12-31 | $4.20 | $0.05 | x |
| 2022-12-31 | $2.21 | $0.05 | x |
| 2023-12-31 | $1.07 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Omega Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -167.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3148.93%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 3.52x
- Recent ROE (-167.93%) is below the historical average (-59.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.94 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.74 Million |
| 2021 | -34.47% | -48029.17% | 0.00x | 1.16x | $-89.22 Million |
| 2022 | -96.85% | -4951.09% | 0.01x | 1.38x | $-113.23 Million |
| 2023 | -167.93% | -3148.93% | 0.02x | 3.52x | $-103.23 Million |
Industry Comparison
This section compares Omega Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Omega Therapeutics Inc (OMGA) | $11.54 Million | 0.00% | 12.23x | $1.05 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |